Literature DB >> 18339444

Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus.

Dedee F Murrell1, Sarah Dick, A R Ahmed, Masayuki Amagai, Maria A Barnadas, Luca Borradori, Jean-Claude Bystryn, Giuseppe Cianchini, Luis Diaz, David Fivenson, Russell Hall, Karen E Harman, Takashi Hashimoto, Michael Hertl, Nico Hunzelmann, Pilar Iranzo, Pascal Joly, Marcel F Jonkman, Yasuo Kitajima, Neil J Korman, Linda K Martin, Daniel Mimouni, Amit G Pandya, Aimee S Payne, David Rubenstein, Hiroshi Shimizu, Animesh A Sinha, David Sirois, Detlef Zillikens, Victoria P Werth.   

Abstract

Our scientific knowledge of pemphigus has dramatically progressed in recent years. However, despite the availability of various therapeutic options for the treatment of inflammatory diseases, only a few multicenter controlled trials have helped to define effective therapies in pemphigus. A major obstacle in comparing therapeutic outcomes between centers is the lack of generally accepted definitions and measurements for the clinical evaluation of patients with pemphigus. Common terms and end points of pemphigus are needed so that experts in the field can accurately measure and assess disease extent, activity, severity, and therapeutic response, and thus facilitate and advance clinical trials. This consensus statement from the International Pemphigus Committee represents 2 years of collaborative efforts to attain mutually acceptable common definitions for pemphigus. These should assist in development of consistent reporting of outcomes in future studies.

Entities:  

Mesh:

Year:  2008        PMID: 18339444      PMCID: PMC2829665          DOI: 10.1016/j.jaad.2008.01.012

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  1 in total

Review 1.  Introducing a novel Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) in pemphigus.

Authors:  Martin Pfütze; Andrea Niedermeier; Michael Hertl; Rüdiger Eming
Journal:  Eur J Dermatol       Date:  2007-02-27       Impact factor: 3.328

  1 in total
  73 in total

1.  Glucocorticoid sensitivity and proinflammatory cytokines pattern in pemphigus.

Authors:  Rosangela Soares Chriguer; Ana Maria Roselino; Margaret de Castro
Journal:  J Clin Immunol       Date:  2012-03-10       Impact factor: 8.317

2.  Rituximab for autoimmune blistering diseases: recent studies, new insights.

Authors:  L Lunardon; A S Payne
Journal:  G Ital Dermatol Venereol       Date:  2012-06       Impact factor: 2.011

Review 3.  Seeking approval: present and future therapies for pemphigus vulgaris.

Authors:  Xuming Mao; Aimee S Payne
Journal:  Curr Opin Investig Drugs       Date:  2008-05

Review 4.  Pemphigus.

Authors:  Michael Kasperkiewicz; Christoph T Ellebrecht; Hayato Takahashi; Jun Yamagami; Detlef Zillikens; Aimee S Payne; Masayuki Amagai
Journal:  Nat Rev Dis Primers       Date:  2017-05-11       Impact factor: 52.329

5.  Facilitated subcutaneous immunoglobulin treatment in pemphigus vulgaris.

Authors:  Massimo Radin; Dario Roccatello; Simone Baldovino; Savino Sciascia
Journal:  BMJ Case Rep       Date:  2018-05-30

Review 6.  [Principles of glucocorticoid therapy].

Authors:  J Ehrchen
Journal:  Hautarzt       Date:  2012-12       Impact factor: 0.751

7.  Pemphigus vulgaris in a pregnant woman and her neonate.

Authors:  Sameera Begum Kader Ibrahim; B M Yashodhara; Shashikiran Umakanth; Sachchithanatham Kanagasabai
Journal:  BMJ Case Rep       Date:  2012-06-28

8.  Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts.

Authors:  Dedee F Murrell; Benjamin S Daniel; Pascal Joly; Luca Borradori; Masayuki Amagai; Takashi Hashimoto; Frédéric Caux; Branka Marinovic; Animesh A Sinha; Michael Hertl; Philippe Bernard; David Sirois; Giuseppe Cianchini; Janet A Fairley; Marcel F Jonkman; Amit G Pandya; David Rubenstein; Detlef Zillikens; Aimee S Payne; David Woodley; Giovanna Zambruno; Valeria Aoki; Carlo Pincelli; Luis Diaz; Russell P Hall; Michael Meurer; Jose M Mascaro; Enno Schmidt; Hiroshi Shimizu; John Zone; Robert Swerlick; Daniel Mimouni; Donna Culton; Jasna Lipozencic; Benjamin Bince; Sergei A Grando; Jean-Claude Bystryn; Victoria P Werth
Journal:  J Am Acad Dermatol       Date:  2011-11-05       Impact factor: 11.527

9.  Reliability and convergent validity of two outcome instruments for pemphigus.

Authors:  Misha Rosenbach; Dedee F Murrell; Jean-Claude Bystryn; Sam Dulay; Sarah Dick; Steve Fakharzadeh; Russell Hall; Neil J Korman; Julie Lin; Joyce Okawa; Amit G Pandya; Aimee S Payne; Mathew Rose; David Rubenstein; David Woodley; Carmela Vittorio; Benjamin B Werth; Erik A Williams; Lynne Taylor; Andrea B Troxel; Victoria P Werth
Journal:  J Invest Dermatol       Date:  2009-04-09       Impact factor: 8.551

10.  Pediatric pemphigus vulgaris: durable treatment responses achieved with prednisone and mycophenolate mofetil (MMF).

Authors:  Andrea Baratta; Diana Camarillo; Christine Papa; James R Treat; Aimee S Payne; Suzanne S Rozenber; Albert C Yan
Journal:  Pediatr Dermatol       Date:  2012-07-02       Impact factor: 1.588

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.